Liver Pathology in Obesity

ABSTRACT

Obesity-related liver disease, particularly nonalcoholic fatty liver disease and its more severe form nonalcoholic steatohepatitis, is being increasingly recognized as a common liver disease in developed countries and represents hepatic manifestation of the metabolic syndrome. Nonalcoholic steatohepatitis results in progressive fibrosis, cirrhosis, and end-stage liver disease, with its increased incidence of hepatocellular carcinoma. Liver biopsy remains the gold standard in detection, evaluation, staging, and grading of nonalcoholic steatohepatitis. Liver biopsy also provides an important tool to detect concomitant liver disease that may accelerate the progression of steatohepatitis in these patients.

Surgical or drug-induced weight loss has been documented to reduce the amount of inflammation, to induce regression of fibrosis, and, in some cases, to cause a reversal of cirrhosis in obese patients with steatohepatitis. Pretreatment or intraoperative liver biopsy should be performed to assess the presence of steatohepatitis, and stage and grade of steatohepatitis.

This article will discuss obesity-related liver diseases, focusing on pathologic features in liver biopsies from obese patients, obesity-related hepatocellular carcinoma, and the effect of weight loss treatment on histopathology.

KEYWORDS

Steatohepatitis - steatosis - obesity - nonalcoholic fatty liver disease - fibrosis - fat

REFERENCES

• 1 Yanovski S, Yanovski J A. Obesity.  N Engl J Med. 2002;  346 591-602
• 2 Kopelman P G. Obesity as a medical problem.  Nature. 2000;  404 635-643
• 3 Hedley A A, Ogden C L, Johnson C L et al.. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002.  JAMA. 2004;  291 2847-2850
• 4 Flegal K M. Trends in body weight and overweight in the U.S. population.  Nutr Rev. 1996;  54 S97-100
• 5 Youssef W I, McCullough A J. Diabetes mellitus, obesity, and hepatic steatosis.  Semin Gastrointest Dis. 2002;  13 17-30
• 6 Wanless I R, Lentz J S. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors.  Hepatology. 1990;  12 1106-1110
• 7 Dixon J B, Bhathal P S, O'Brien P E. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.  Gastroenterology. 2001;  121 91-100
• 8 Ratziu V, Giral P, Charlotte F et al.. Liver fibrosis in overweight patients.  Gastroenterology. 2000;  118 1117-1123
• 9 Marceau P, Biron S, Hould F S et al.. Liver pathology and the metabolic syndrome X in severe obesity.  J Clin Endocrinol Metab. 1999;  84 1513-1517
• 10 Adler M, Schaffner F. Fatty liver hepatitis and cirrhosis in obese patients.  Am J Med. 1979;  67 811-816
• 11 Caldwell S H, Oelsner D H, Iezzoni J C et al.. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease.  Hepatology. 1999;  29 664-669
• 12 Dixon J B, O'Brien P E, Bhathal P S. A wider view on diagnostic criteria of nonalcoholic steatohepatitis [reply].  Gastroenterology. 2002;  122 841-842
• 13 Angulo P, Keach J C, Batts K P, Lindor K D. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.  Hepatology. 1999;  30 1356-1362
• 14 Ratziu V, Trabut J B, Poynard T. Fat, diabetes, and liver injury in chronic hepatitis C.  Curr Gastroenterol Rep. 2004;  6 22-29
• 15 Farrell G C. Drugs and steatohepatitis.  Semin Liver Dis. 2002;  22 185-194
• 16 Montero J L, Muntane J, Fraga E et al.. Orlistat associated subacute hepatic failure.  J Hepatol. 2001;  34 173
• 17 Durazo F A, Lassman C, Han S H et al.. Fulminant liver failure due to usnic acid for weight loss.  Am J Gastroenterol. 2004;  99 950-952
• 18 Erlinger S. Gallstones in obesity and weight loss.  Eur J Gastroenterol Hepatol. 2000;  12 1347-1352
• 19 Chow W H, Gridley G, Fraumeni Jr J F. Obesity, hypertension, and the risk of kidney cancer in men.  N Engl J Med. 2000;  343 1305-1311
• 20 Schapira D V, Clark R A, Wolff P A et al.. Visceral obesity and breast cancer risk.  Cancer. 1994;  74 632-639
• 21 Murphy T K, Calle E E, Rodriguez C et al.. Body mass index and colon cancer mortality in a large prospective study.  Am J Epidemiol. 2000;  152 847-854
• 22 Theise N D, Schwartz M, Miller C et al.. Macroregenerative nodules and hepatocellular carcinoma in forty-four sequential adult liver explants with cirrhosis.  Hepatology. 1992;  16 949-955
• 23 Nair S, Mason A, Eason J et al.. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?.  Hepatology. 2002;  36 150-155
• 24 Ratziu V, Bonyhay L, Di Martino V et al.. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis.  Hepatology. 2002;  35 1485-1493
• 25 Angulo P, Lindor K D. Treatment of nonalcoholic fatty liver: present and emerging therapies.  Semin Liver Dis. 2001;  21 81-88
• 26 Andersen T, Gluud C, Franzmann M B et al.. Hepatic effects of dietary weight loss in morbidly obese subjects.  J Hepatol. 1991;  12 224-229
• 27 Luyckx F H, Scheen A J, Desaive C et al.. Effects of gastroplasty on body weight and related biological abnormalities in morbid obesity.  Diabetes Metab. 1998;  24 355-361
• 28 MacDonald Jr K G, Long S D, Swanson M S et al.. The gastric bypass operation reduces the progression and mortality of non-insulin-dependent diabetes mellitus.  J Gastrointest Surg. 1997;  1 213-220
• 29 Scopinaro N, Gianetta E, Adami G F et al.. Biliopancreatic diversion for obesity at eighteen years.  Surgery. 1996;  119 261-268
• 30 Kral J G, Thung S N, Biron S et al.. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis.  Surgery. 2004;  135 48-58
• 31 Silverman E M, Sapala J A, Appelman H D. Regression of hepatic steatosis in morbidly obese persons after gastric bypass.  Am J Clin Pathol. 1995;  104 23-31
• 32 Dixon J B, Bhathal P S, Hughes N R et al.. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss.  Hepatology. 2004;  39 1647-1654
• 33 Luyckx F H, Lefebvre P J, Scheen A J. Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss.  Diabetes Metab. 2000;  26 98-106
• 34 Ludwig J, Viggiano T R, McGill D B et al.. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.  Mayo Clin Proc. 1980;  55 434-438
• 35 Matteoni C A, Younossi Z M, Gramlich T et al.. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.  Gastroenterology. 1999;  116 1413-1419
• 36 Le T H, Caldwell S H, Redick J A et al.. The zonal distribution of megamitochondria with crystalline inclusions in nonalcoholic steatohepatitis.  Hepatology. 2004;  39 1423-1429
• 37 Ludwig J, McGill D B, Lindor K D. Review: nonalcoholic steatohepatitis.  J Gastroenterol Hepatol. 1997;  12 398-403
• 38 Washington K, Wright K, Shyr Y et al.. Hepatic stellate cell activation in nonalcoholic steatohepatitis and fatty liver.  Hum Pathol. 2000;  31 822-828
• 39 Lavine J E, Schwimmer J B. Nonalcoholic fatty liver disease in the pediatric population.  Clin Liver Dis. 2004;  8 549-558
• 40 Abdelmalek M, Ludwig J, Lindor K D. Two cases from the spectrum of nonalcoholic steatohepatitis.  J Clin Gastroenterol. 1995;  20 127-130
• 41 Shimada M, Hashimoto E, Taniai M et al.. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis.  J Hepatol. 2002;  37 154-160
• 42 Orikasa H, Ohyama R, Tsuka N et al.. Lipid-rich clear-cell hepatocellular carcinoma arising in non-alcoholic steatohepatitis in a patient with diabetes mellitus.  J Submicrosc Cytol Pathol. 2001;  33 195-200
• 43 Tsuneyama K, Kaizaki Y, Doden K et al.. Combined hepatocellular and cholangiocarcinoma with marked squamous cell carcinoma components arising in non-cirrhotic liver.  Pathol Int. 2003;  53 90-97
• 44 Regimbeau J M, Colombat M, Mognol P et al.. Obesity and diabetes as a risk factor for hepatocellular carcinoma.  Liver Transpl. 2004;  10 S69-S73
• 45 Neuschwander-Tetri B A, Caldwell S H. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference.  Hepatology. 2003;  37 1202-1219
• 46 Levi G, Bu-Ghanim M, Xu R et al.. A 48-year-old obese man with a 3-cm liver lesion and a history of hemochromatosis and lymphoma.  Semin Liver Dis. 2004;  24 327-332
• 47 Shalhub S, Parsee A, Gallagher S F et al.. The importance of routine liver biopsy in diagnosing nonalcoholic steatohepatitis in bariatric patients.  Obes Surg. 2004;  14 54-59
• 48 Brunt E M. Nonalcoholic steatohepatitis.  Semin Liver Dis. 2004;  24 3-20
• 49 Brunt E M, Neuschwander-Tetri B A, Oliver D et al.. Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens.  Hum Pathol. 2004;  35 1070-1082